Why the study?
To evaluate the level of hemolysis and potential acquired von Willebrand syndrome after Carmat bioprosthetic total artificial heart (Aeson; A-TAH) implantation.
Does the Carmat bioprosthetic total artificial heart cause hemolysis or acquired von Willebrand syndrome compared to Heartmate II or III in adult patients?
Population
10 adult patients receiving A-TAH support
Comparison
A-TAH support vs control subjects and adult patients receiving Heartmate II or Heartmate III support
Design
Comparative cohort study and computational fluid dynamics simulation
Loading...
The Carmat bioprosthetic total artificial heart demonstrates biological hemocompatibility without causing hemolysis or acquired von Willebrand syndrome, unlike continuous-flow left ventricular assist devices.
Does the Carmat bioprosthetic total artificial heart cause hemolysis or acquired von Willebrand syndrome compared to Heartmate II or III in adult patients?
The Carmat bioprosthetic total artificial heart demonstrates biological hemocompatibility without causing hemolysis or acquired von Willebrand syndrome, unlike continuous-flow left ventricular assist devices.
A 2022 study studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: